Literature DB >> 1648540

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

T L Fong1, A M Di Bisceglie, J G Waggoner, S M Banks, J H Hoofnagle.   

Abstract

We assessed the prevalence and clinical significance of antibodies to hepatitis C virus among a cohort of 148 patients with chronic hepatitis B virus infection. Sixteen patients (11%) had anti-hepatitis C virus detectable by enzyme-linked immunoassay. The results from eight of these patients were positive by recombinant immunoblot assay. The results of recombinant immunoblot assay testing were not consistent; therefore the analysis of the patients' data was based on anti-hepatitis C virus enzyme-linked immunoassay results. Patients with chronic hepatitis B with anti-hepatitis C virus were more likely to be cirrhotic (44% vs. 21%) and to have decompensated liver disease (24% vs. 6%). Hepatitis B virus replication appeared to be suppressed in patients with both infections as measured by hepatitis B virus-associated DNA polymerase activity (mean = 2,055 vs. 2,555 cpm). Human immunodeficiency virus infection was more common in the anti-hepatitis C virus positive group (36% vs. 11%). Thus hepatitis C virus appears to suppress hepatitis B virus replication and to cause more severe liver disease in patients with chronic hepatitis B infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648540     DOI: 10.1002/hep.1840140111

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

1.  Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection.

Authors:  E Rodríguez-Iñigo; J Bartolomé; N Ortiz-Movilla; C Platero; J M López-Alcorocho; M Pardo; I Castillo; V Carreño
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  [Study of HCV infection and viremia in patients with posttransfusion hepatitis in China].

Authors:  Z Y Tang; D L Yang; Z Q Yu; L J Hao
Journal:  J Tongji Med Univ       Date:  1995

Review 3.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

4.  Prevalence of anti-HCV antibodies in chronic liver disease in the Czech Republic.

Authors:  J Stránský; M Horejsová; A Chlumská; E Honzáková; J Vandasová; V Nĕmecek
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

Review 5.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

6.  Frequency of HIV and HCV Co-Infections in Chronic HBV Patients Referred to Taleghani Hospital, Tehran, Iran from 2006 to 2010.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Pedram Azimzadeh; Mohsen Vahedi; Shohreh Almasi; Sara Romani; Afsaneh Sharifian; Faramarz Derakhshan; Mohammad Reza Zali
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

7.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

8.  High prevalence of hepatitis C in Egyptian patients with chronic liver disease.

Authors:  I A Waked; S M Saleh; M S Moustafa; A A Raouf; D L Thomas; G T Strickland
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

Review 9.  Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.

Authors:  Yun-Fan Liaw
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

10.  Hepatitis type C virus infection in patients with type B chronic liver disease.

Authors:  T Doi; G Yamada; H Endo; H Nishimoto; M Takahashi; R Miyamoto; S Fujiki; H Shimomura; M Mizuno; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1992-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.